Cartesian Therapeutics, Inc. Research And Development Expense

• Cartesian Therapeutics, Inc. showed an increase of +28.7% in Research And Development Expense from 2024 to 2025.
• This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2015: $5.31 million | Q3 2015: $5.48 million | Q1 2016: $6.65 million | Q2 2016: $6.00 million | Q3 2016: $6.02 million | Q1 2017: $11.04 million | Q2 2017: $10.99 million | Q3 2017: $9.50 million | Q1 2018: $11.14 million | Q2 2018: $14.41 million | Q3 2018: $11.89 million | Q1 2019: $7.35 million | Q2 2019: $12.13 million | Q3 2019: $8.10 million | Q1 2020: $14.72 million | Q2 2020: $10.73 million | Q3 2020: $13.96 million | Q1 2021: $13.00 million | Q2 2021: $14.46 million | Q3 2021: $20.95 million | Q1 2022: $17.69 million | Q2 2022: $19.18 million | Q3 2022: $16.54 million | Q1 2023: $18.62 million | Q2 2023: $17.78 million | Q3 2023: $13.00 million | Q1 2024: $9.74 million | Q2 2024: $12.66 million | Q3 2024: $11.40 million | Q1 2025: $14.67 million | Q2 2025: $14.87 million | Q3 2025: $13.80 million.
• Over the full 12 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Research And Development Expense has grown by 453.4%.
• Historical annual values: Fiscal year 2025: $58.03 million | Fiscal year 2024: $45.11 million | Fiscal year 2023: $71.26 million | Fiscal year 2022: $72.38 million | Fiscal year 2021: $68.74 million | Fiscal year 2020: $54.51 million | Fiscal year 2019: $42.74 million | Fiscal year 2018: $47.69 million | Fiscal year 2017: $45.17 million | Fiscal year 2016: $29.70 million | Fiscal year 2015: $22.98 million | Fiscal year 2014: $10.49 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026